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Abstract 
Measuring single cell responses to Lapatinib in a heterogeneous population 
 
Preety Priya 
Advisory Professor: Dr. Prahlad Ram, Ph.D. 
 
Cancer is not one disease but a saga of diseases and is the outcome of disturbed homeostasis in 
the normal cells due to the deregulation of its genetic makeup. With advent of technologies that 
allow detailed molecular characterization of tumors, targeted therapies have emerged as a more 
promising and specific mode of treatment. However, a major challenge with targeted therapy is 
the acquired resistance in the cancer cells to these therapies, quite often very rapidly in the 
course of a few months. One of the major targets in cancer has been the EGFR/ErbB2 network in 
breast and other cancer types. Prior work from our lab and others have shown alterations in the 
cellular network whereby compensatory upregulation of alternative pathways such as glucose 
uptake and metabolism can lead to acquired resistance to anti- EGFR/ErbB2 therapy in breast 
cancer to Lapatinib [1]. However, one the of the very important unanswered questions at the 
cellular and molecular level is the mechanisms that leads to selection of cells that are resistant to 
Lapatinib whereby there exists two possibilities: 1. Cells are intrinsically resistant and are less 
likely to respond to the drug and get selected for 2. Cells switch response phenotype over time 
leading to increased metabolism and resistance. In this proposal I will develop a predictive 
computational model that can be used to dynamically model the response of cells to lapatinib and 
determine what underlying response mechanisms can lead to adaptive resistance cell populations 
based on single cell dynamics. Models to predict the internal environment of the cell by the 
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phenotype and vice versa will be a very novel approach to understand the adaptive resistance 
mechanism and to overcome it. Here, I propose to utilize an Agent-based cellular automata 
model to represent the cellular microenvironment, which can track the cellular response to drugs 
by tracking the metabolite or signaling levels which can then be experimentally constrained and 
tested using live cell FRET reporter constructs. 
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1 Introduction 	  
Human epidermal growth factor receptor 2 (Her2) is overexpressed in almost 20-30% of 
breast cancers (A.C. Wolf M.E. Hammond 2007). Trastuzumab targets Her2 and has been an 
effective mode of treatment for women with Her2-positive breast cancer and administered with 
the adjuvant therapy. Lapatinib is given to patients who don’t respond to Trastuzumab. Lapatinib 
is a small-molecule kinase inhibitor, which interrupts both Her2 and epidermal growth factor 
receptor (EGFR) pathways. Lapainib is given orally alone or in combination with chemotherapy 
and with Trastuzumab. But patients acquire resistance to Lapatinib within a year. Multiple 
studies have been focused to understand the underlying mechanism of development of the 
resistance to Lapatinib. This study is focused on developing the computational model to study 
the development of resistance to Lapatinib in a heterogeneous population of cells. Previous 
studies have indicated the perturbation in the activity levels of AMP-activated protein kinase 
(AMPK) and Mitogen activated protein kinases (MAPK) in the resistant cells. So, in this study 
the computational model is built to investigate the cross talk between AMPK and MAPK and to 
examine if their correlation can attribute to the development of Lapatinib resistance in cells. The 
agent based modeling system has been utilized to build the computational model. The model is 
constrained by the variables such as different media conditions (with or without Lapatinib), 
activity levels of AMPK & MAPK, a phenotypic switch in the heterogeneous cell population and 
a cell death rate.  	  	  	  	  
	   2	  
1.1 HER2-positive-EGFR/ErbB2 
 
Breast carcinoma is among the most common reasons for cancer morbidity in women 
across the world based on the breast cancer statistics (Susan G. Komen Statistics, 2014). Present 
research focuses on targeting molecular factors, which can improve the diagnosis and treatment 
of the disease. Her2 oncogene is recognized as one of the important molecular markers for 
characterizing breast cancer subtypes. Tumors that express Her2 are called Her2 positive breast 
cancer and targeted therapies to Her2 are utilized clinically.  Normally one copy of Her2 gene 
(ErbB2 gene family) is present in chromosome 17 of the cell; however, the Her2 positive tumors 
overexpress the Her2 gene. [2]  
 
Signal transduction pathways in breast epithelial cells include activation of the 
transmembrane tyrosine kinase growth factor receptors (EGFR/HER1, HER2, HER3, and 
HER4). This signal transduction pathway regulates cellular growth, survival and differentiation 
involving PI3K/Akt and the Ras/Raf/MEK/MAPK pathways.   
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Figure 1: The ErbB signaling pathway [3] 
ErbB family receptors dimerize upon ligand binding. This dimerization leads to the activation of 
intracellular tyrosine kinase. Ligand binding leads the heterodimerization of Her2 -Her3. FKHR, 
forkhead in rhabdomyosarcoma; Grb2, growth factor receptor-bound protein 2; GSK-3, glycogen 
kinase synthase-3; MAPK, mitogen-activated protein kinase; mTOR, molecular target of 
rapamycin; PI3K, phospatidyl-inositol 3-kinase; PTEN, phosphatase and tensin homologue 
deleted on chromosome 10; SOS, son-of-sevenless guanine nucleotide exchange factor. 
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Her2 (also known as Neu or ErbB2), a receptor tyrosine kinase belonging to the human 
epidermal growth factor receptor (EGFR) family that also includes EGFR/Her1, Her3, and Her4, 
is an important component of cell-signaling networks, and is implicated in the growth of a 
variety of cancers [4-7]. The receptors of the EGFR family activate through dimerization (Figure 
1), which is promoted by the binding of ligands from the EGF family to the receptors’ 
extracellular regions (‘ectodomains’). This activation process relies on a number of allosteric 
interactions in the extracellular, transmembrane, and intracellular portions of the receptor [8, 9], 
which lead to the formation of a specific asymmetric active dimer of the intracellular kinase 
domains [10]. Her2 is unique in the family in that it does not homodimerize under normal 
conditions, and its ectodomain does not bind ligands. Instead, it activates through 
heterodimerization with other members of the family (EGFR and Her3, in particular) when they 
are bound to ligands [6, 11]. This change in structural conformation leads to activation of 
tyrosine kinase domain intrinsic to the cell followed by subsequent phosphorylation of specific 
tyrosine kinase residues. These tyrosine kinase residues serve as docking site for signaling 
molecules, which leads to the activation of many downstream signaling pathways like MAPK 
pathway, PI3K pathway. Approximately 20-30% [12] of breast cancer cases have an 
amplification of the Her2 gene (~2-20 folds). This amplification of the Her2 gene leads to 
excessive cell signaling and cell division and ultimately tumor formation. This makes Her2 
positive breast cancer one of the aggressive subtypes and thus, Her2 is a valuable treatment 
target.   
 
For therapies to be effective various diagnostic techniques have been introduced to 
confirm the amplification of the Her2 gene and also predict the sensitivity to cytotoxic drugs. 
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Currently four testing techniques are being used: the IHC test (ImmunoHistoChemistry) 
diagnoses the excess of Her2 protein in cancer cells and results are given as 0 (negative), 1+ 
(negative), 2+ (borderline) and 3+ (positive, i.e., overexpression of Her2 protein), FISH 
(Florescence In Situ Hybridization) detects the excess copies of Her2 gene in cancer cells and the 
results show positive for amplification and negative for no Her2 amplification, SPoT-Light Her2 
CISH Test (Subtraction Probe Technology Chromogenic In Situ Hybridization) and Inform Her2 
Dual ISH test also detects the extra copies of Her2 like FISH and delivers results as positive for 
amplification and negative for no amplification.  
 
1.2 Targeted Therapy-Trastuzumab 
 
The aggressiveness of Her2 positive breast cancer correlates with the poor survival rate. 
Her2 positivity and its high level of expression in tumor tissues make it an ideal target for the 
therapies. Presently there are two approved Her2-targeted therapies: monoclonal antibodies 
(Trastuzumab) and small molecule inhibitors (Lapatinib).   
 
Trastuzumab (Herceptin) is humanized anti-HER2 monoclonal antibody, which 
specifically targets Her2 in cancerous cells. Trastuzumab was approved in 1998 by FDA as a 
first line treatment for the metastatic disease in combination with paclitaxel. Trastuzumab is used 
for patients who have already received chemotherapy. The antigen specific sites of Trastuzumab 
bind to the extracellular domain of Her2 receptor and prevent the binding of ligand and in turn 
impede the activation of intracellular tyrosine kinase.  Trastuzumab therapy has significantly 
increased the response rates and overall survival in patients with Her2+ metastatic breast cancer.  
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Mice model studies have shown the inhibition of angiogenesis by Trastuzumab in Her2 positive 
breast cancer. Preclinical studies have suggested that Trastuzumab recruits immune effector cells 
responsible for antibody-dependent cytotoxicity.  In clinical studies, the joint analysis of 
National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 and North Central Cancer 
Treatment Group (NCCTG) N9831 trials showed that addition of trastuzumab to adjuvant 
chemotherapy significantly improves disease free survival by 52% compared to chemotherapy 
only. This study also led to the approval of Trastuzumab for the adjuvant treatment of Her2+ and 
node-positive cancer in 2006.  
 
But there are multiple mechanisms through which patients develop resistance to 
Trastuzumab. Nagata et al. suggested the role of PTEN loss (decreased expression) attributing to 
the resistance [13]. PTEN inhibits AKT inducing growth arrest in cells. Low levels of PTEN 
insufficiently inhibit AKT and cells continue to grow not responding to Trastuzumab. Activation 
of alternate pathways like IGF-IR could also contribute to the resistance [14]. IGF-1R is a 
tyrosine kinase receptor, which, when overexpressed, leads to cell proliferation and 
metastatisation. Expression of other Her receptors like Her3 or EGFR can also be another reason. 
Expression of TGF-a plays a potentially important role in development of resistance. 
Upregulation of src activity (pernelle lavaud, fabric andre 2014) or MUC4, increased VEGF 
expression (pernelle lavaud, fabric andre 2014) and overexpression of c-MET (pernelle lavaud, 
fabric andre 2014) are also studied as the mechanisms of development of resistance to Lapatinib. 
(pernelle lavaud, fabric andre 2014). 
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Table 1: Approved Her2 targeting drugs 
The table lists clinically approved monoclonal antibodies and small molecule kinase inhibitors, 
which target Her2 in various types of cancer. The monoclonal antibodies and their target epitope 
is mentioned. 
 
  
ErbB targeting drug Targeted therapy Type of Cancer 
Trastuzumab Monoclonal Antibody (domain 
IV of Her2) 
Her2 positive breast  
Afinitor Tyrosine kinase inhibitor Her2 negative breast 
Lapatinib Tyrosine kinase inhibitor Her2 positive breast 
Pertuzumab Monoclonal Antibody (domain 
II of Her2) (2011 gloria 
Fuentes, Maurizio scaltriti) 
Her2 positive breast 
Afatinib Tyrosine kinase inhibitor NSC-Lung  
Cetuximab Monoclonal Antibody (domain 
III of Her2) 
NSC-Lung, Colorectal  
Erlotinib Tyrosine kinase inhibitor NSC-Lung, Pancreas, Renal 
Everolimus Tyrosine kinase inhibitor Kidney, Her2 negative breast 
Panitumumab Monoclonal Antibody (domain 
III of Her2) 
Her2 positive breast 
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Various strategies are considered for overcoming the trastuzumab resistance in patients. Small-
molecule kinase inhibitors are considered as effective anticancer therapeutics. These kinase 
inhibitors target the ATP binding site of the intracellular domain of kinases and inhibits the 
downstream signaling. Lapatinib is one of the clinically approved small tyrosine kinase 
inhibitors. Contrary to Trastuzumab, it targets and inhibits the intracellular tyrosine kinase 
domain of Her2. Lapatinib interrupts Her2 signaling and also enhances Trastuzumab dependent 
antibody-dependent cell-mediated cytotoxicity (ADCC) (pernelle lavaud, fabric andre 2014). 
Some of the small molecule inhibitors studied under combinatorial therapy are: Lapatinib, 
Gefitinib, Erlotinib. 
 
1.3 Targeted Therapy-Lapatinib (Tykerb) 
 
Lapatinib is a small molecule dual inhibitor of tyrosine kinase. Preclinical trials have 
shown its efficacy in blocking EGFR and Her2 mediated signal transduction. Lapatinib 
competitively binds to the ATP binding pocket of EGFR/Her2, which prevents the ATP 
molecule to bind to the protein kinase domain, shown in the figure. This inhibits the auto-
phosphorylation and activation of downstream signal transduction.  
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 Figure	  2:	  Dual	  tyrosine	  kinase	  inhibition	  by	  Lapatinib	  	  The	  dimerization	  leads	  to	  the	  activation	  of	  intracellular	  kinase	  domain.	  Lapatinib	  bonds	  to	  the	  ATP	  binding	  site	  of	  the	  tyrosine	  kinase.	  This	  blocks	  the	  transmission	  of	  signal	  to	  downstream	  molecules	  and	  the	  growth	  signaling	  is	  interrupted.	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Phase II clinical trial of Lapatinib in combination with Paclitaxel has shown an overall response 
rate of 33% in Her2 positive metastatic breast cancer [16]. Lapatinib is administered orally and it 
is speculated that it may cross the blood-brain barrier and reduce the risk of CNS metastasis [16]. 
In the combination with Capacitabine, Lapatinib has shown efficacy in improving progression-
free survival (). The combination of Lapatinib with Trastuzumab has been investigated in phase 
III study and was found to improve progression free survival and overall survival ().  
 
Primary and acquired resistance in patients has restricted treatment-involving Lapatinib. 
Phase II trials have shown the response rate of 20-30% to Lapatinib in Her2-positive metatstatic 
breast cancer [17]. Patients responding to the treatment have also acquired resistance to the 
treatment within a year. The mechanism of drug sensitivity and acquired resistance has not been 
fully understood. Studies have shown that the resistance can be attributed to ER (estrogen 
receptor) and PR (progesterone receptor) signaling upregulation due to increased activity levels 
of FOXO3a and Bcl-2 [18]. Another study has shown the activation of AXL [19]. 
Overexpression of AXL leads to invasiveness of breast cancer. Src overactivation has also been 
considered as a potential mechanism to Lapatinib resistance in various studies [20]. In addition 
studies have also shown an upregulation of metabolic functions can lead to decreased lapatinib 
sensitivity and adaptive resistance [20]. 
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1.4 MAPK & AMPK 
 
Overexpression of Her2 leads to increased downstream Ras-Raf-mitogen-activated protein 
kinase signaling. Mitogen activated protein kinases belong to CMGC kinase 
(CDK/MAPK/GSK3/CLK) group and are involved in cell signaling for proliferation, 
differentiation, gene expression, cell survival and apoptosis [21]. They undergo phosphorylation 
in their activation loop to become active. The MAPK cascade involves multiple layers of 
pathways. The ERK1/2 pathway is a known MAPK pathway. ERK pathway is involved in cell 
proliferation, which makes it a target pathway for cancer studies where cells show elevated 
proliferation rate. Lapatinib inhibits MAPK-Erk1/2 activity in Her2 positive breast cancer cell 
lines; tumor xenografts; and in clinical tumor biopsies. Work from the Ram Lab has shown the 
complete inhibition of Her family in presence of Lapatinib but the MAPK activity was partially 
inhibited. [20] 
 
From previous studies conducted in the Ram lab, SKBr3 cells were made resistant to 
Lapatinib by treating them with Lapatinib over a year. Western blot analysis had shown that 
Lapatinib could inhibit Her2 family phosphorylation but could only partially inhibit the activity 
of MAPK. Along with the partial inhibition of MAPK from western blot, gene profiling 
indicated the up regulation of glucose uptake and metabolism pathways. Western blot analysis 
also indicated the upregulation of AMPK.  
 
AMPK is involved in maintaining cellular energy homeostasis. The heterotrimeric subunit 
of AMPK is responsible for its enzyme activity. It is the metabolic regulator in glucose uptake, 
fatty acid oxidation and biogenesis of glucose transporters [22]. AMPK activation positively 
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regulates signaling pathways, which replenishes the ATP supply in fatty acid oxidation and 
autophagy. AMPK also negatively regulates ATP-consuming process like gluconeogenesis, lipid 
and protein synthesis. 
 
High activity levels of AMPK were also seen in Lapatinib resistant cells. Since tumors are 
dependent on aerobic glycolysis (Warburg effect) for energy (ATP), metabolic proteins, fatty 
acid and nucleic acid biosynthesis [23], the activation of metabolic stress response via AMPK 
might contribute to Lapatinib resistance.  
 
 
Figure 3: Cross talk between AMPK and MAPK to develop resistance against Lapatinib Lapatinib	   inhibits	   intracellular	   Her2	   signaling.	   The	   potential	   crosstalk	   between	   AMPK	   at	  the	   downstream	   of	   glucose	   pathway	   and	   MAPK	   at	   the	   downstream	   of	   growth	   signaling	  pathway	  can	  lead	  to	  the	  cellular	  resistance	  to	  Lapatinib.	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 The figure shows that AMPK, playing a crucial role in maintaining cellular energy 
homeostasis, is at the downstream of glucose pathways and MAPK is at the downstream of 
growth factor signaling pathway. The activity levels of MAPK and AMPK can be correlated to 
study the Lapatinib resistance. A computational model can represent this biological scenario and 
can give the flexibility to study the speculated mechanism of resistance if there is a cross talk 
between AMPK and MAPK.  
 
With the intent of designing the computational model to study the resistance in cells, 
various factors have to be considered, some of which are: heterogeneity in the MAPK and 
AMPK activity levels across the cellular population, doubling time of cells, growth and division 
rates, death rate of cell, cellular interactions with neighboring cells, phenotypic switch leading to 
enhanced or reduced activity levels of MAPK and AMPK between cells, different media 
conditions. Designing and constraining the computational model requires tracking the activity 
levels of AMPK and MAPK. A FRET (Florescence	  resonance	  energy	  transfer) based analysis 
in microfluidic system can be efficient to track the activity levels in a heterogeneous population 
of cells. Microfluidic system involves study of cellular population in a fluid media including the 
manipulation and analysis of cultured cells. Microfluidics give the advantage of controlling the 
media and environmental conditions (like oxygen, glucose, CO2) and performing time point 
studies. So, in my study, cells can be monitored under different media conditions and activity 
levels of AMPK and MAPK can be tracked over time. Fluorescence studies involve the tracking 
of energy emitted by the fluorophore associated with the protein. FRET can be employed to track 
the activity levels of AMPK and MAPK in cells under the microfluidic system.   
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1.5 FRET: Florescence resonance energy transfer  	  
We know that there is heterogeneity in the population of cells, which can be critical to their 
chance of survival and proliferation in different environmental conditions. So, it is important to 
track variability among single cells and their behavior across the cellular population. Highly 
sensitive detection and analysis of a single cell has been a challenge for researchers. In my study 
I have used florescence resonance energy transfer to track individual cells. FRET generates 
fluorescence signals sensitive to molecular conformation with a separation of approx. 10 nm. 
Florescence microscopy produces contrast by exploiting the display of light emission based on 
ground and excited states of electrons. [24-26] 
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Figure 4: Florescence Resonance Energy Transfer [27] 
The FRET system consists of Ligand domain, sensor domain connected by a linker protein. 
Fluorophores are attached to both domains. Activation of protein of interest leads to the 
conformational change bringing the two domains together. This brings the two fluorophores next 
to each other and energy is transmitted and emitted in the form of fluorescence. 
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 FRET is unique in providing signals sensitive to intra and an intermolecular interaction 
resolving molecular intersection and a conformation with a spatial resolution far exceeding the 
inherent diffraction limit of conventional optical microscopy and also is compatible with super 
resolution techniques.  The FRET technique involves transfer of energy from a fluorophore in 
excited state being a donor to another chromophore which acts as acceptor [28]. 
 
Single cell FRET imaging has been applied in determination of the pathway of tumor cell 
apoptosis study [24]. In this study the spatio-temporal dynamics of caspase-3 and caspase-8 
activation in living cells real time with FRET technique on SCAT3 and Bid-CFP. To acquire the 
temporal profile of caspase, the SCAT3 expressing cells were treated with PDT. The 
fluorescence microscope collected the cellular emission of fluorescence. Recently, scientists 
have implemented genetically encoded FRET sensors for measurement of pyruvate transport, 
production and mitochondrial pyruvate consumption [29].  
 
A previous study in the Ram lab had established that there is a heterogeneous population 
of cells, which behave differently in the presence of Lapatinib in the media. The phosphorylation 
was tracked using FRET system on microfluidic plate. In the experiment EKAR (ERK activity 
reporter) FRET sensors were used to track ERK phophorylation. The EKAR sensor consists of a 
fluorescent protein FRET pair, a substrate phosphorylation peptide from Cdc25C containing the 
consensus MAPK target sequence and proline directed phosphor-binding domain. ERK 
activation leads to the phosphorylation of the substrate sequence followed by subsequent binding 
by the phosphor-binding domain. This leads to the conformational rearrangement and brings the 
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receptor and donor domain of FRET close enough for the interaction to take place between the 
flurophores during the ERK activation. [30] 
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Figure 5: FRET imaging 
 
MCF10A cells in complete media in a microfluidic system. After 1hour Lapatinib was added to 
the media and cells were tracked for 63hours. FRET images were taken every 15 minutes. The 
fluorescence shows the heterogeneity in the levels of MAPK in cellular population. In the 
presence of Lapatinib the cells become inactive towards the end of experiment emitting no 
fluorescence.   
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 The figure shows the population of cells with heterogeneous MAPK activity levels. The 
cells with high levels of MAPK are shown in yellow and red colors and cells with lower MAPK 
levels have green bluish colorization.  The cells were tracked for 63h and the cells with lower 
MAPK levels were observed to die earlier than the cells with high MAPK activity levels. At the 
end of 63h all the cells had died. This experiment indicated that high levels of MAPK could 
contribute to the differential sensitivity to Lapatinib.  
 
1.6 Agent Based Model 	  
In the study of complex diseases like cancer, scientific illation of any vision involves 
theoretical, experimental and computational approaches. Computational models (mathematical 
modeling and simulation) are especially important as they come from a thorough understanding 
of theoretical exploration. Agent based modeling is a computational approach, which 
demonstrates the evolution of a dynamic system by exploring and simulating its individual 
constituents. It is an unbiased approach describing live systems evolving over time by analyzing 
the interconnection of its individual agents. 
 
Agent based modeling is a suitable representation of biological systems due to variety of reasons: 
[31] 
1. The individual agents of the system set the rules and guidelines of the model. These rules are 
flexible and can be modified as the model evolves. 
2. The model evolves by the interaction of the individual agents with each other and with the 
system. This results in tracking intricate details by modeling the system for more accuracy. 
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3. Agent-based model can be constructed even without the complete knowledge of the system. 
So, in the initial phase the model can still be built based on the ideology representing the 
simplest level of the vision. 
4. Considering the random exhibit of behavior of biological systems, the agent-based models can 
determine the rule based on the proportionality of the behavior in consideration to the entire 
system and then convert it to the rules between individual agents. 
5. It excludes the difficulties during the isolation of human systems and ethical problems related 
to the experimentation due to its existence on virtual system. 
6. Also, in cases where the biological systems are very complex with multiple interactions and 
range of inputs, the agent-based model proves more appropriate to obtain results and multiple 
runs. 
 
Many modeling software are available to run agent based models. Software like Swarm, 
NetLogo and AnyLogic are widely utilized to apply ABM. This algorithm has been largely used 
for representing biomedical applications including population dynamics [32] and human immune 
system (Association for Computing Machinery. 2006.). Zhihui Wang ET. Al. used ABM 
simulation for non-small cell lung cancer studies to study the spatio- temporal expansion of 
virtual glioma cells in 2D [33]. 
 
These studies have shown the usefulness of ABM simulation from molecular scale up to 
cellular level and also the applicability and flexibility of this platform in cancer studies. In my 
study ABM has been used as predictive models to study the behavior of single cells in a 
heterogeneous population. 
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2 Hypothesis 	  
Intracellular MAPK and AMPK activity in a heterogeneous cellular population 
contributes to the development of resistance to Lapatinib.  
   
To test the hypothesis, the cells were treated with Lapatinib and the activity levels of 
individual cells were tracked using live cell reporters (FRET) and agent based model was used to 
build predictive models to predict molecular activities of AMPK and MAPK and correlate with 
phenotypes like cell division and cell death. 
 
 
3 Specific Aims 	  
Aim 1: Development of computational model 
Rationale: To computationally model the cellular activity to mimic the biological behavior in 
computational simulations 
 
Aim 2: Simulations of single cell and the population dynamics in response to perturbation by 
EGF and Lapatinib  
Rationale: To computationally investigate the intracellular activity with cells in different media 
and stress conditions and the corresponding changes in cell proliferation.  
 
Aim 3: Computationally predict cellular behavior that leads to adaptive resistance 
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Rationale: Correlate phenotypic switch with cell death rate to study the development of 
resistance under different conditions of media and rates of cell death and cell phenotype 
switching. 	  	  
4 Methodology 
 
To study Lapatinib resistance based on the correlation between MAPK and AMPK 
levels, the computational models were based on the hypotheses that intrinsic population of cell 
gives rise to resistant cells. The alternate hypothesis to this is that cells switch phenotype under 
stress of Lapatinib. The hypothesis is tested based on the computational agent based modeling 
system. To simulate the agent-based model, the Netlogo framework was used. The model built 
uses default grids (also called patches), which are referred to here as culture dishes. The patches 
provide the area for the agents to move and perform actions. The model holds 4 kinds of agents 
(called turtles in NetLogo): high MAPK high AMPK, high MAPK low AMPK, low MAPK high 
AMPK and low MAPK low AMPK. The functions associated to agents are to move, divide, 
switch between different kinds of agents . The concept involved is that the cells (agents) divide 
more quickly in the presence of growth stimulator and only certain class of agents survive and 
grow in the presence of Lapatinib (growth inhibitor). These agents are regarded as lapatinib 
resistant cells, which further give rise to a population of cells completely resistant to lapatinib. 
The environmental conditions are invoked using stochastic impulses to gain more realistic 
understanding of effect of environment perturbations on the agents. 
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4.1 Conceptual Model and Logic implementation in the prototype 	  	  
 
 
 
 
 
 
 
 
 
 
 
  
Heterogeneous	  population	  of	  cell a.	  Switch	  between	  phenotypes b.	  Cell	  death	  at	  constant	  rate 
Heterogeneous	  population	  of	  cell a. Switch between phenotypes b.	  Cell	  division	  rate	  increases 
Heterogeneous	  population	  of	  cell a.	  Switch	  between	  phenotypes	  at	  different	  rates b.	  Cell	  death	  differs	  for	  different	  phenotypic	  class 
EGF	  
Lapatinib	  
Complete	  media	  
Cells	   surviving	   will	   give	  rise	   to	   a	   population	   of	  cells	   resistant	   to	  Lapatinib	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The heterogeneous population of cells switch between different phenotypic classes and 
die at a constant rate (3%) in the presence of complete media. When EGF is stochastically added, 
the division rate of cells is enhanced. When Lapatinib is added to the media, it acts as growth 
inhibitor and increases the cell death rate in the cellular population, which also varies between 
the different phenotypic classes. The model tracks the number of surviving cells in each 
phenotypic class with different environmental conditions.  
 
4.2 States 
 
All the agent sets in this agent-based model have 3 states: movement, division and death. 
Apart from that the agents also switch between four phenotypic classes and attain their 
characteristics.   
 
Movement: At any time step all turtles can move in a patch in their neighborhood chosen at 
random. 
Division: At any time step the turtles divide to two turtles of same phenotypic class. 
Death: At any time step the life counter of agent is decremented by the user input value. If the 
life counter of an agent reaches 0 then the agent is removed from the simulation.  
Switch: turtles switch between different phenotypic class. The rate of switching is user defined.  
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4.3 Transition and Simulation 
 
To stimulate the process, the model is initiated with a user-defined number of agents in 
each phenotypic class. In the program the ‘set’ button resets the code and ‘go’ button starts 
running the code till the code terminates.  
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 Figure	  6:	  Start button to initiate the process 
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The model consists of 4 phenotypic groups of cells representing heterogeneous 
population of cells, which are high MAPK high AMPK, high MAPK low AMPK, low MAPK 
high AMPK and low MAPK low AMPK. The constructor class represents the interface look of 
cells: 
 
set-default-shape highhigh "circle" 
  create-highhigh initial-highhigh  
  [ 
    set color green 
    set size 1.5  
    ;set energy random (high-gain) 
    setxy random-xcor random-ycor 
  ] 
 
The initial number of cells in each class is set by the slider (11 in this case), which can be 
set to any number in between 0 to 100.  
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 Figure	  7:	  Slider bar for user-input of initial cell count 
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The basic functionality of the cells represented by the program is the cell movement, cell 
division and cell death.  
The move function makes the cells to move in the program: 
 
 
to move   
  rt random step-size 
  avoid-walls 
  lt random step-size 
  fd 1 
end 
 
The function here indicates the cells to move stepwise and forward one step at a time. 
The cell division is indicated by the below code: 
 
to reproduce-highlow  
     
     hatch 1 [random-float 360 fd 1]   
   
end 
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The hatch command is the primitive command of the Netlogo, which creates new cells 
identical to their parents and asks the daughter cells to run the commands directed for it. 
The cell death is shown by the death function: 
to death-lap-low   
  [ die ] 
end 
 
The die command is also primitive Netlogo command, which makes the cells to die. 
 
The cells with different MAPK and AMPK levels differ in their cell division rate, which 
is set by the slider at the user interface.  
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 Figure	  8:	  Slider bar at user interface for cell division rate 
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The initial cell death is set to 10% for all classes of cells. The cells with different 
phenotypic composition behave differently under different stress conditions and in the presence 
of growth stimulator. Also, these cells switch phenotype, which is shown by the code: 
 
switch [set breed one-of ( list highlow lowhigh lowlow ) set color pink] 
 
The code here indicates the cells switch phenotype at random to other phenotypic classes 
and the cells with switched phenotype are pink in color. 
 
 In the presence of EGF the growth of the cells are increased which is directed and 
controlled by the slider in the interface. When Lapatinib is switched on cells with different 
phenotype is measured for their different cell death rate. The sliders in the user interface of the 
program control these different conditions.    
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 Figure	  9:	  Slider bar for cell division in presence of EGF 
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The counter function keeps a track of cell numbers from all the four classes and as the 
cells switch the classes.  
  
	   35	  
 
 Figure	  10:	  Counter to keep track of the number of cells 
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 Figure	  11:	  Histogram indicating the number of cells in different classes with time 
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5 Results and Discussion 
 
5.1 Development of Computational Agent based model 
  
Agent based modeling is a computational method used to study complex systems. It 
comprises of agents and their interactions with each other and with their environments in a 
computer-simulated environment. The code (in SCALA) for the model is written from the point 
of view of each of the agent types represented in the model and their environments. Behavior can 
be described in terms of activities or conditional statements, which constrains the model to 
mimics the biological scenario. After identifying the agents and its environment the model is 
constrained with a set of rules for the behavior.  
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(a)   	  (b) 	  	  	  	  (c)	    
 
Figure 12: Model Version 0: Simulation of cell division replicated in computational model 
(a) Culture dish seeded with initial number of cells 
(b) Cells dividing to two daughter cells during the simulation 
(c) The culture dish becoming confluent with the cells and the simulation ends  
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The computational model in the figure represents computational simulation of cell 
division. The agents in the model are the cells and their environment is the culture dish. The 
model consists of a cell culture dish with initial number of cells. The variable in the model are 
the number of cells and doubling time of the cells. The model is constrain by the following rules:  
• Culture dish is seeded with initial number of cells 
• Cells divide at their doubling time 
• The process (simulation) ends when the culture dish is confluent 
In the simulation when the cell reaches its doubling time, it divides to two daughter cells. The 
simulation runs till the culture dish becomes confluent with the cells. 
 
5.2 Simulations of single cell and the population dynamics in response to perturbation by 
EGF and Lapatinib  	  
After the designing of the agent-based model for the cell division, the next model designs 
cells (agents) treated under different media conditions (environments).  
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Cells in Media  
 
 
Figure 13: Cells in different phenotypic group under complete media. 
Cells in red have low MAPK and low AMPK. Cells in orange have low MAPK and high AMPK 
Cells in blue have high MAPK and low AMPK. Cells in green have high MAPK and high 
AMPK. Cells change to pink during transitioning to different phenotype. The graph is cellular 
population in each group tracked over various time points.  
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The figure shows a heterogeneous population of cells in a complete media. During the simulation 
the cells divide to populate the culture dish. They also, switch from one group to other group, 
shown in pink. The simulation indicates the uninterrupted cell growth in the complete media. 
The graph shows the number of cells in each class over the period of time. From the graph it is 
evident that the number of cells increases in each phenotypic group with time. In this simulation 
cells are not in any kind of environmental stress allowing them to divide, grow, switch and die at 
their own pace without any pressure.	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Cells in EGF 
 Figure	  14:	  Cells in various phenotypic groups in presence of EGF 
The graph indicates the number of cells in each group over time. The cell count increases 
overtime in the presence of growth stimulator, EGF 
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 The figure shows a heterogeneous population of cells in media and EGF is spiked in the 
media after 10 ticks (number maintained throughout the simulation for all the media conditions). 
The graph shows the rapid growth in number of cells with High MAPK and low AMPK since 
AMPK is the growth suppressor and comparatively low cell division and growth with cell having 
high MAPK and high AMPK. The model also shows the phenotypic switch in cells from high 
MAPK to low MAPK and high AMPK to low AMPK. After switching the phenotype the cells 
behave in their newly switched phenotype. The simulation indicates the rapid cell growth in 
media with growth stimulator EGF. The graph shows the rapid increase in groups of cells with 
high MAPK. Also, the cells with low MAPK may switch to high MAPK increase the cell count 
of high MAPK group. 
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Lapatinib in media 
 
 Figure	  15:	  Cells	  in	  various	  phenotypic	  groups	  in	  presence	  of	  Lapatinib	  
The graph indicates the number of cells in each group over time. The cell count in each group 
decreases over time in presence of Lapatinib 	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 The figure shows a heterogeneous population of cells in media and Lapatinib is added to 
the media. The graph shows the rapid decline in the cell division in the cells. The simulation also 
involves the cells switching their phenotype from low to high MAPK and AMPK and vice versa. 
The graph indicates the time point growth of cells resistant to Lapatinib and decline in the 
number of Lapatinib sensitive cells. At the end of the simulation all the cells in the culture dish 
die. 
The aim here was to understand cellular behavior in different media conditions. The 
growth stimulator EGF enhances the cell division while Lapatinib restricts the cell division 
ultimately letting the cells to die. So, considering the phenotypic switch and regulating the 
cellular death rate can give more information about the correlation of the levels of MAPK and 
AMPK and cellular response to drug Lapatinib. 	  
5.3 Computationally predict cellular behavior that leads to adaptive resistance 	  
 To predict the cellular behavior, cells were put under different stress conditions in 
presence of Lapatinib:  
1. Death rate  
2. Phenotype switch 
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            Graph 1: clustered stack chart for the death rate vs phenotype in each phenotypic group 
The number of cells in each group is stacked and all the groups are clustered for various 
death rates under different phenotypic switch rate. 
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The computational model is used to run the simulation under different cellular stress 
conditions. In the presence of Lapatinib the death rate and phenotypic switch was regulated and 
the number of cells in each phenotypic group was tracked. The stacked bars indicate the number 
of cells in each group at the end of each simulation with various phenotypic switch rates. The 
bars from each group are then clustered together for different cell death rates. The death rate was 
varied between 1, 2 and 3% in the presence of Lapatinib and the phenotype switch between 
different classes of cells was varied between 10, 25, 50,75 and 90% respectively. The graph 
indicates the significant survival and increase in number of cells with low MAPK and high 
AMPK levels in comparison to the other phenotypic groups. The cell counts from individual 
groups have been shown in graph below (figure 16). The	   simulations	   show	   that	   with	   high	  AMPK	   levels	   and	   low	  MAPK	   levels	   in	   cells	   they	   can	  develop	   resistance	  against	  Lapatinib.	  These	  cells	  can	  then	  give	  rise	  to	  a	  population,	  which	  are	  totally	  resistant	  to	  Lapatinib.	  These	  results	   predict	   that	   there	   is	   a	   cross	   talk	   between	   AMPK	   and	   MAPK,	   which	   leads	   to	   the	  development	  of	  resistance	  in	  cells.	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  (a)	  10%	  Phenotype	  switching	  
 
 
 
 
(b)	  25% Phenotype switching 
 
 
 
	  
	   49	  
(c)	  50% Phenotype switching 
 
 
 
 
(d)	  75% Phenotype switching 
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(e)	  90% Phenotype switching 
 
 	  Figure	   16	   (a-­‐e):	   	   The	   simulation	   at	   10,25,50,75	   and	   90%	   phenotypic	   switch	   with	   death	  rates	   of	   1,2	   and	   3%.	   The	   simulation	   of	   low	  MAPK	   and	   high	  AMPK	   (LH)	   group	   of	   cells	   is	  graphed.	  The	  table	  shows	  the	  number	  of	  cells	  in	  LH	  group	  in	  different	  stress	  conditions.	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 Table	  2:	  Death	  Rate	  Vs	  Phenotype	  Switch	  	  Cells	   in	  high	  MAPK	  low	  AMPK	  group	  are	  the	  survivors	  under	  Lapatinib	  media	  and	  varied	  cell	  death	  and	  phenotypic	  switch	  conditions.	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 Tracking the cells in high MAPK and low AMPK group, the heatmap shows the number 
of cells surviving at a given time point with different phenotype and death rate conditions. The 
model shows that cells with high AMPK and low MAPK have better survival in Lapatinib media 
condition. These cells can further give rise to the resistant population.  The	  result	  suggests	  that	  high	   levels	   of	   AMPK	   can	   contribute	   to	   the	   development	   of	   Lapatinib	   resistance	   in	   cells.	  AMPK	   is	   a	   major	   player	   in	   cellular	   growth	   and	   metabolism	   regulation.	   Cells	   with	   high	  AMPK	  levels	  signifies	  high	  AMP/ATP	  ratio	  and	  activates	  catabolic	  pathways	  inhibiting	  the	  anabolic	  pathways	   [34].	  This	  allows	   the	  cells	   to	  survive	  during	   the	   intervals	  of	  metabolic	  stress,	  which	  was	  induced	  by	  Lapatinib	  in	  this	  case.	  From	  the	  table	  2	  it	  is	  evident	  that	  cells	  survival	  rate	  increases	  with	  increase	  in	  phenotypic	  switch	  rate.	  	  	  	  
6 Summary and Future Directions 	  
 Almost 20-30% of breast cancer cases overexpress Her2 receptor tyrosine kinase. 
Targeting tyrosine kinase receptors is also front-line therapy along with monoclonal antibodies. 
Lapatinib is one such clinically approved tyrosine kinase inhibitor for the treatment of Her2-
overexpressed breast cancer. However, a major concern with the therapy is that patients develop 
resistance against Lapatinib within a year. The underlying mechanism of Lapatinib resistance is 
still under speculation. It has been shown previously that Lapatinib could successfully inhibit 
Her2 family but it only partially inhibits MAPK signaling. Also, the gene expression data had 
shown the upregulation of glucose uptake and metabolism pathways. Activity of pAMPK was 
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upregulated as per the previous work in the lab. This indicated that activities of both MAPK and 
AMPK could contribute to the development of Lapatinib resistance in cells. To understand the 
mechanism of resistance, the computational models were developed. The agent-based model is a 
rule based computational model, which focuses on interactions between agents and with their 
environments. Agent based modeling system has been extensively used in systems biology to 
understand various biological behaviours. The modular approach of agent based modeling 
system gives the flexibility to modify any part of the model based on the biological behavior of 
the system at any given point without affecting the entire model. SCALA was used as the 
programming language to code for the model and the simulations were run using the NetLogo 
software. The various models showed cells in different media conditions. The simulation tracked 
the number of cells surviving and dividing under different environmental conditions. The model 
was constrained by different death rates and phenotypic switch between different cellular 
phenotype. The results showed that variations in death rate and phenotypic switch affect the 
cellular sensitivity to Lapatinib in the media. At a death rate of 1 resistant cell population is 
highest in number and they give rise to a population of cells resistant to Lapatinib. This resistant 
population then grows till the end of the simulation indicating their never-ending growth.  
 
 The results support the hypothesis that there is a cross talk between signaling and 
metabolic pathways, which directs the development of resistance to Lapatinib treatment in Her-2 
positive patients. Lapatinib has been previously shown to induce apoptosis and cell death in 
HER2 overexpressing cells [36]. 
 The agent-based models show the different stress conditions where cells switch 
phenotypes and die at different percentages. The models show that at higher phenotypic switch 
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to high AMPK and low MAPK the cells become insensitive to cell death pathways. This can be 
due to phosphorylation of TSC2 by AMPK, which enhances GTPase activity and decreases 
growth-signaling pathways [35]. It can also be attributed to the reciprocal relation between AMP 
and mTORC1, which directly interacts with ERK, activity which allows the cells to coordinate 
energy requiring anabolic processes with energy availability – under conditions of energy 
deprivation, activation of AMPK can limit energy-consuming processes such as protein synthesis 
via repression of mTORC1 [37]. The model shows that cells behave differently in different 
media conditions. In presence of EGF the cellular division rate increased leading to the increased 
cellular population in less time making the culture dish confluent. In the presence of Lapatinib, 
growth inhibitor, there was increase in the cell death. Cells where tracked under different cell 
death and phenotypic switch conditions in the presence of Lapatinib. The models show a 
significant increase in the cellular population with the phenotypic switch to high AMP and low 
MAPK levels in the presence of Lapatinib media condition. This indicates that under stress 
conditions (Lapatinib in media) cell can switch phenotype to survive. These cells can give rise to 
a population of cells, which will be resistant to the drug. The model prediction provides an 
alternative perspective of the development of resistance suggesting that there is heterogeneity in 
the cellular population and cells switch phenotypes randomly, which can lead to the development 
of resistance. The experimental tests following the model should aim at tracing levels of MAPK 
and AMPK in the heterogeneous cellular population. Because the cell death is involved in the 
study it is important to track the cell cycle and cell doubling time. The following experiment can 
be studying cellular population under different media condition with varying environmental 
factors. This model can be implemented in different cell type studies and can incorporate more 
conditions to replicate the cellular behavior for the study. This model can used to perform studies 
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on the 3D cell culture where the cell behavior will differ from inside and outside of the cluster. 
The model can also be utilized to perform a comparative study between multiple drugs and 
media conditions. The model also involves time point studies.  
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